DE:67N0 Stock Latest News
Company AnnouncementsEdding Genor Posts Promising Phase I Data for Trispecific Cancer Antibody GB2681w ago
Company AnnouncementsEdding Genor Wins NMPA Nod for Phase II Trial of GB268 in Advanced Colorectal Cancer3w ago
Company AnnouncementsEdding Genor Chairman to Boost Stake as Company Launches Share Buyback2M ago
Company AnnouncementsEdding Genor Posts Solid Interim Revenue as It Deepens Push Into Breast Cancer Therapies2M ago
Company AnnouncementsEdding Genor Warns of First‑Half Loss as Drug Procurement Hits Sales2M ago
Company AnnouncementsEdding Genor Sets Board Meeting to Review Interim Results and Dividend Plan2M agoCompany AnnouncementsEdding Genor’s Jing Zhu Da Sub-Licensing Deal Collapses After Upstream License Termination2M ago
Company AnnouncementsEdding Genor Realises US$48.4 Million from Sale of Candid Stake After UCB Takeover3M ago- Company AnnouncementsEdding Genor Launches Up to 10% Share Buyback Ahead of 2027 AGM3M ago
Company AnnouncementsEdding Genor Wins NMPA Nod for Phase Ib/II Trial of Trispecific Breast Cancer Antibody GB2684M ago
Company AnnouncementsEdding Genor shareholders back board, accounts and 10% buyback mandate at AGM4M ago
Company AnnouncementsEdding Genor Chair to Boost Shareholding in USD1 Million Plan4M agoCompany AnnouncementsEdding Genor Reshapes Company Secretariat as Hong Kong Grants Governance Waiver5M ago
Company AnnouncementsEdding Genor’s GB261 Gains Momentum as UCB Moves to Acquire Licensee Candid Therapeutics6M ago
- Company AnnouncementsEdding Genor Calls 2026 AGM, Seeks Fresh Share Repurchase and Issuance Mandates6M ago
Company AnnouncementsEdding Genor Boosts Profit as Landmark Biotech Merger Drives New Growth7M ago- Company AnnouncementsEdding Genor Details Board and Committee Structure7M ago
Company AnnouncementsEdding Genor Sets March 2026 Board Meeting to Approve 2025 Results7M ago
Company AnnouncementsEdding Genor Expands Global Rights to Key siRNA Drug as It Streamlines Nanopeptide Collaboration8M ago